Centessa Pharmaceuticals (CNTA) Return on Equity (2022 - 2025)
Centessa Pharmaceuticals (CNTA) has disclosed Return on Equity for 4 consecutive years, with 0.48% as the latest value for Q4 2025.
- Quarterly Return on Equity rose 5.0% to 0.48% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.48% through Dec 2025, up 5.0% year-over-year, with the annual reading at 0.43% for FY2025, 31.0% up from the prior year.
- Return on Equity for Q4 2025 was 0.48% at Centessa Pharmaceuticals, up from 0.75% in the prior quarter.
- The five-year high for Return on Equity was 0.41% in Q3 2024, with the low at 0.75% in Q3 2025.
- Average Return on Equity over 4 years is 0.59%, with a median of 0.61% recorded in 2023.
- The sharpest move saw Return on Equity increased 18bps in 2024, then tumbled -34bps in 2025.
- Over 4 years, Return on Equity stood at 0.61% in 2022, then increased by 0bps to 0.61% in 2023, then grew by 14bps to 0.52% in 2024, then grew by 9bps to 0.48% in 2025.
- According to Business Quant data, Return on Equity over the past three periods came in at 0.48%, 0.75%, and 0.63% for Q4 2025, Q3 2025, and Q2 2025 respectively.